G. Vainer, Ghadeer Zatara, Lingkang Huang, K. Emancipator, S. Nuti
{"title":"503: PD-L1 22C3抗体LDT方案在BenchMark XT和PD-L1 IHC 22C3 pharmDx上的分析比较:泛肿瘤和食管癌样本的分析","authors":"G. Vainer, Ghadeer Zatara, Lingkang Huang, K. Emancipator, S. Nuti","doi":"10.1158/1538-7445.AM2021-503","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10518,"journal":{"name":"Clinical Research (Excluding Clinical Trials)","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract 503: Analytical comparison of a PD-L1 22C3 antibody LDT protocol on the BenchMark XT and PD-L1 IHC 22C3 pharmDx: Analysis of pan-tumor and esophageal cancer samples\",\"authors\":\"G. Vainer, Ghadeer Zatara, Lingkang Huang, K. Emancipator, S. Nuti\",\"doi\":\"10.1158/1538-7445.AM2021-503\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10518,\"journal\":{\"name\":\"Clinical Research (Excluding Clinical Trials)\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research (Excluding Clinical Trials)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.AM2021-503\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research (Excluding Clinical Trials)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract 503: Analytical comparison of a PD-L1 22C3 antibody LDT protocol on the BenchMark XT and PD-L1 IHC 22C3 pharmDx: Analysis of pan-tumor and esophageal cancer samples